Coronary Artery Bypass is surgery in which a healthy blood vessel taken from another part of the body is used to make a new path for blood around a blocked artery leading to the heart. This restores the flow of oxygen and nutrients to the heart. Also called aortocoronary bypass and CAB.
MAQUET Cardiovascular, LLC, a leading provider of cardiovascular technologies, announced today that it has signed a three year contract with HealthTrust Purchasing Group, LP to provide woven and knitted textile vascular grafts to the HealthTrust membership. The contract includes the HEMASHIELD product line and other vascular grafts, which are used to surgically repair or replace damaged blood vessels, including the aorta.
On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
In an innovative new procedure, interventional cardiologist Ramesh Mazhari, MD, is one of only a few in the Washington, DC, region to access the coronary arteries through the radial artery on the inside of the wrist.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced today that it will a host an educational symposium featuring leading cardiovascular surgeons who will discuss the critical issues in caring for today's cardiovascular surgery patients.
Ushering in a new era in comprehensive cardiac care, the Vivian and Seymour Milstein Family Heart Center celebrated its opening today at NewYork-Presbyterian Hospital/Columbia University Medical Center.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has signed a three-year single source provider contract with Novation, the industry's leading supply contracting company, for MAQUET's market-leading VASOVIEW Endoscopic Vessel Harvesting (EVH) Systems.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced today that it has signed a guaranteed two-year contract with Novation, one of the nation's largest group purchasing organizations, to be the sole source provider of surgical devices for beating heart cardiac surgery.
Results from a clinical study presented at the 2009 American Society of Anesthesiologists (ASA) Meeting suggest that elevated preoperative levels of the B-type natriuretic peptide (BNP) biomarker may predict hospital length of stay and mortality after primary coronary artery bypass graft surgery better than measurements of elevated postoperative BNP levels.
MAQUET Cardiovascular LLC, a leading, global provider of cardiovascular technologies, today celebrated and formally opened its new United States headquarters in Wayne, New Jersey. The dedication ceremony was attended by local and state dignitaries, the MAQUET leadership team, and local employees from the company's cardiovascular, critical care and surgical workplace divisions.
MAQUET Cardiovascular announced today that Johannes Bonatti, M.D., Professor of Surgery and Director of Coronary Surgery and Advanced Coronary Interventions at the University of Maryland Heart Center in Baltimore, has completed the world's first use of the MAQUET Minimized ExtraCorporeal Circulation (MECC) system during a successful robotic and fully endoscopic heart surgery. The new cardiopulmonary bypass technology is the first major advancement in perfusion technology in the last decade. It is designed to minimize the effects of traditional heart surgery and aid in minimally-invasive heart surgery without the need to stop the patient's heart from beating.
The October issue of the journal Anesthesiology contains a study reviewing potential adverse effects associated with the timing of a patient's heart surgery; but based on this study, there is no bad time of the day or week or year to have elective coronary artery bypass graft surgery.
HighRoads, the company providing employers – for the first time – complete control over their health care costs and compliance, today announced findings from the industry’s first medical travel request for information (RFI) for Fortune 500 employers to compare health care procedural ethics, quality and costs around the world.
Brain scientists and cardiac surgeons at Johns Hopkins have evidence from 227 heart bypass surgery patients that long-term memory losses and cognitive problems they experience are due to the underlying coronary artery disease itself and not ill after-effects from having used a heart-lung machine.
A study of almost 25,000 coronary artery bypass graft (CABG) patients has shown that receiving blood from another person is associated with a two-fold increase in post-operative infection rates. The research, published in the open access journal BMC Medicine, also found considerable hospital variation in transfusion practices.
Coronary artery bypass surgery provides long-term benefits for children whose hearts and blood vessels are damaged by Kawasaki disease, Japanese researchers report in Circulation: Journal of the American Heart Association.
Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.
Two non-pharmacological interventions-cognitive behavior therapy and supportive stress management-appear more effective than usual care for treating depression after coronary artery bypass surgery, according to a report in the April issue of Archives of General Psychiatry.
In a study comparing the ability of various medical techniques to accurately determine the extent of heart disease and stratify patients according to disease severity, researchers found that myocardial perfusion testing with gated single photon emission computed tomography (gated SPECT) was a more accurate predictor of prognosis in chronic ischemic heart disease (IHD)-a painful condition caused by a temporary reduction of oxygen-rich blood to the heart.
After three years working with investigators from 10 different clinical trials around the world from Brazil to London to Pittsburgh, Stanford University School of Medicine researchers have pooled enough individual patient data to compare the effectiveness of coronary artery bypass surgery with the less-invasive angioplasty procedure on specific groups of patients for the first time.